Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 404 participants.

Also called NCT01973231

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 404 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01973231
  • EudraCT 2012-004984-27
Main results
  • Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial Diabetes care, 2016-09 DOI, PubMed 27311491

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Czechia, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01973231. Randomized; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
Acronym
LIRA-LIXI™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
lixisenatide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01973231
Content hash
5af075ed44745ec2b965ed2ce5e0576d587fc4cb2150c6ac0f9733a3119ca015